CureVac Commences P-llb/lll Trial of CVnCoV for COVID-19

Shots:

• The P-llb/lll HERALD trial will assess the safety and efficacy of CVnCoV (12 µg) in 35,000+ patients aged ≥18yrs. for the treatment of COVID-19 across EU and Latin America. The participants will receive a two-dose schedule of either CVnCoV or PBO
• The study will start with an initial P-IIb part, which is anticipated to seamlessly merge into a P-III efficacy trial
• Following completion of the trial, subjects will continue to be monitored in a 1-year extension study which will collect additional data to evaluate long-term safety, persistence of Abs to SARS-CoV-2 and the occurrence of COVID-19 cases to assess the duration of vaccine efficacy

Click here ­to­ read full press release/ article | Ref: Curevac | Image: MarketWatch